From the 56th Annual Scientific Session of the American College of Cardiology: ARISE: Succinobucol delivers mixed results in phase 3 trial of patients with ACS

Succinobuccol, an investigational monosuccinic acid ester of probucol, was not associated with a reduction in a composite end point of major cardiovascular events in patients diagnosed with acute coronary syndrome (ACS), but use of the agent did result in improvements on certain secondary end points.